SCHEMBL2944803

SCHEMBL2944803

COC(=O)CCCCN1CCCC1=O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
KMT2A Q03164 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
GLA P06280 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
ATM Q13315 1/20 0.46
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19513773 0.98 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A
SCHEMBL27418304 0.95 KMT2A (0.51) SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A
SCHEMBL10645521 0.89 KMT2A (0.54) SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A
SCHEMBL948885 0.84 KMT2A (0.49) SMN1; SMN2KMT2AL3MBTL1RAB9AMEN1
SCHEMBL9702659 0.83 MAPK1 (0.61) SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A
SCHEMBL17662280 0.83 KMT2A (0.48) SMN1; SMN2KMT2AL3MBTL1RAB9AMEN1
Methylpyrrolidone SCHEMBL14832752 0.81 BRD4 (0.57) SMN1; SMN2KMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL6317137 0.81 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A
SCHEMBL2944990 0.80 TSHR (0.49) KMT2ANPC1RAB9AMEN1TSHR
SCHEMBL27339301 0.80 ALDH1A1 (0.49) SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 US disclosed
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 EP disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 US disclosed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 US disclosed
CN-100475777-C Amide type carboxamide derivative TANABE SEIYAKU CO (JP) 2009-04-08 CN disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-7375119-B2 Amide type carboxamide derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-05-20 US disclosed
CN-100344632-C Fused furan compound TANABE SEIYAKU CO (JP) 2007-10-24 CN disclosed
US-20060287329-A1 Amide type carboxamide derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-12-21 US disclosed
CN-1860097-A Amide-type carboxamide derivative TANABE SEIYAKU CO (JP) 2006-11-08 CN disclosed
EP-1666455-A1 AMIDE TYPE CARBOXAMIDE DERIVATIVE TANABE SEIYAKU CO., LTD. (JP) 2006-06-07 EP disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 US disclosed
CN-1723210-A Fused furan compound TANABE SEIYAKU CO (JP) 2006-01-18 CN disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 EP disclosed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 SMN1; SMN2 3151/4885KMT2A 1500/4885L3MBTL1 4087/4885
US-20060287329-A1 Amide type carboxamide derivative F12, F11, F13A1 SMN1; SMN2 3486/4885KMT2A 18/4885L3MBTL1 2218/4885
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885KMT2A 2033/4885L3MBTL1 3708/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 SMN1; SMN2 3067/4885KMT2A 1518/4885L3MBTL1 4101/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 SMN1; SMN2 4490/4885KMT2A 1957/4885L3MBTL1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.